Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Without releasing specific figures, Pfizer said Monday that treatment with ... Pfizer said it plans to discuss with the FDA the potential for full approval of Braftovi in metastatic colorectal ...

US FDA approves AbbVie-Pfizer's treatment for intra-abdominal ... a person familiar with the matter said on Monday. Becton Dickinson looks to divest life sciences unit at $30 billion valuation ...

Although it is waiting on full analysis of the final results, Pfizer intends to present its findings in a meeting with the FDA to support full approval. Speaking ahead of World Cancer Day on 4 ...

Approval from the FDA means that J&J’s Janssen unit has stolen a march on its rivals who are also developing drugs for this niche - Pfizer/Astellas with Xtandi (enzalutamide), Bayer/Orion’s ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it ... fitelparvovec. Other Approved Gene Therapies to Treat Hemophilia Pfizer received FDA approval for two gene ...

2025 Healthcare & Pharmaceuticalscategory US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections February 7, 2025 ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo ... improvement in overall survival (OS), a key secondary endpoint in ...

People with hemophilia A or B got two new treatments: Pfizer’s Hympavzi (marstacimab) and Novo Nordisk’s Alhemo (concizumab). The FDA also gave ... drug to be approved in decades.

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Also Read: Pfizer Eyes $20 Billion Revenue From Acquisitions ... Price Action: PFE stock is up 2.76% at $26.81 at the last check on Monday.